Literature DB >> 28397265

MRI surveillance of vestibular schwannomas without contrast enhancement: Clinical and economic evaluation.

Daniel H Coelho1, Yang Tang2, Brian Suddarth2, Mohammed Mamdani1.   

Abstract

OBJECTIVES: To determine if high-resolution T2-weighted (HRT2) magnetic resonance imaging (MRI) is a comparably accurate and economical alternative to the gold standard of contrast-enhanced T1-weighted (T1C) MRI for surveillance of know vestibular schwannomas (VSs). STUDY
DESIGN: Retrospective case-control analysis, systematic review, and economic evaluation.
METHODS: Vestibular schwannoma size in anteroposterior, mediolateral, and superoinferior axes were measured by two neuroradiologists, both blinded to previous measurements, for 50 randomized patients with T1C and HRT2 on two separate occasions. Measurements were assessed by Pearson product-moment correlation coefficients, and differences were analyzed by Student t test. Once the data were analyzed, appropriate economic evaluation was performed utilizing institutional-, federal-, and literature-based estimates of cost and incidence/prevalence.
RESULTS: Pearson correlations (r) between T1C and HRT2 were 0.991 and 0.973 for radiologists 1 and 2, respectively, with no statistically significant differences (P ≤ 0.05) between imaging techniques. Intraobserver and interobserver reliability estimates (κ) were 0.88 to 1 for both T1C and HRT2, indicating very high reliability. Cost-minimization analysis demonstrated cost and charge differences of $148.02 and $1,284 per patient per scan, respectively. This represents an overall cost and charge savings for this 50-patient cohort of $7,401 and $64,200, respectively.
CONCLUSION: HRT2 imaging is a highly reliable and lower-cost alternative to T1C for follow-up surveillance scans in patients with VS. LEVEL OF EVIDENCE: 2C. Laryngoscope, 128:202-209, 2018.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  MRI; Vestibular schwannoma; contrast; health economics; observation

Mesh:

Substances:

Year:  2017        PMID: 28397265     DOI: 10.1002/lary.26589

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  The impact of MRI steady-state sequences as an additional assessment modality in vestibular schwannoma patients after LINAC stereotactic radiotherapy or radiosurgery.

Authors:  Julian P Sauer; Thomas M Kinfe; Bogdan Pintea; Andreas Schäfer; Jan P Boström
Journal:  Strahlenther Onkol       Date:  2018-05-23       Impact factor: 3.621

2.  Should we be moving to a national standardized non-gadolinium MR imaging protocol for the surveillance of vestibular schwannomas?

Authors:  Stuart Currie; David Saunders; Jeremy Macmullen-Price; Sanjay Verma; Philip Ayres; Caroline Tait; Ceryl Harwood; Andrew Scarsbrook; Ian J Craven
Journal:  Br J Radiol       Date:  2019-01-23       Impact factor: 3.039

3.  The prediction of the tumor size of a vestibular schwannoma by clinical performance and vestibular function tests.

Authors:  Yujuan Zhou; Weidong Zhao; Liang Tian; Jing Yu; Yasheng Yuan; Jing Wang
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

Review 4.  Recent advances in MRI of the head and neck, skull base and cranial nerves: new and evolving sequences, analyses and clinical applications.

Authors:  Philip Touska; Steve E J Connor
Journal:  Br J Radiol       Date:  2019-09-24       Impact factor: 3.039

5.  Development of a model to predict vestibular schwannoma growth: An opportunity to introduce new wait and scan strategies.

Authors:  Mayke A Hentschel; Gerjon Hannink; Stefan C A Steens; Jef J S Mulder; Maroeska M Rovers; Henricus P M Kunst
Journal:  Clin Otolaryngol       Date:  2020-11-06       Impact factor: 2.597

Review 6.  Repeat stereotactic radiosurgery for progressive vestibular schwannomas after previous radiosurgery: a systematic review and meta-analysis.

Authors:  Anne Balossier; Jean Régis; Nicolas Reyns; Pierre-Hugues Roche; Roy Thomas Daniel; Mercy George; Mohamed Faouzi; Marc Levivier; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2021-04-13       Impact factor: 3.042

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.